Primary and Secondary Hemostasis in Elective Coronary Artery Bypass Graft Surgery (HEMOCOR)

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Status: Completed

Conditions: Coronary Disease

Treatments: Other: screening coagulation abnormalities

Study type: Observational

Funder types: Other

Identifiers

NCT00825981

2008/10DEC/350

Details and patient eligibility

About

Patients undergoing elective coronary artery bypass graft surgery (CABG) are treated with platelet inhibitors to reduce myocardial infarction and mortality.However, this can increase perioperative bleeding. A retrospective analysis of the data in our institution has revealed a significant increase in transfusion requirements after elective CABG since 5 years. The aim of our study is to observe if this increase in transfusion requirements is due to platelet inhibitors or due to other coagulation abnormalities resulting from other anticoagulants.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• coronary artery bypass graft surgery with or without cardiopulmonary bypass

Exclusion criteria

• emergency; redo cardiac surgery; combined cardiac surgery; patients with renal insufficiency; patients with acquired coagulation abnormalities

Trial design

100 participants in 1 patient group

coronary artery bypass graft

Description:

patients undergoing elective coronary artery bypass graft with or without cardiopulmonary bypass

Treatment:

Other: screening coagulation abnormalities